SAN FRANCISCO, CA, USA & SHANGHAI, China I February 07, 2025 I AceLink Therapeutics, Inc., a clinical-stage biotech company developing next-generation oral substrate reduction therapies (SRTs), presented interim data from its ongoing Phase 2 clinical study of AL01211 in treatment-naïve, classic male Fabry disease patients. These findings were highlighted in a late-breaking oral platform presentation at the 2025 WORLD Symposium in San Diego, California. The ongoing Phase 2 open-label study is eva

// NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES // VANCOUVER, BC, Feb. 7, 2025 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (" BioVaxys" or the " Company") is pleased to announce, further to its news release of January 10, 2025, and January 23, 2025, an extension of its previously announced non-brokered private placement offering of units of the Company (the " Units") at a price of $0.05 per Unit (the " Private Placement").

CHENGDU, China, Feb. 7, 2025 /PRNewswire/ -- KeyMed Biosciences (HKEX: 02162) today announced the National Medical Products Administration (the " NMPA") of China has recently approved the supplemental New Drug Application (the " sNDA") of Stapokibart (anti-IL-4Rα monoclonal antibody, trade name: Kangyueda (康悦达), for the treatment of seasonal allergic rhinitis. The approval is based on a multi-center, randomized, double-blind, placebo-controlled phase III study to confirm the efficacy and safety

The global pharmaceutical landscape has dramatically shifted as 2025 approaches, marking a significant reshuffle among the top players. Pfizer has regained its position as the leader in pharmaceutical revenue, with a notable resurgence in its oncology division, showing potential to challenge the top cancer drug revenue spots. This news, while not entirely surprising given earlier trends, sets the stage for fierce competition. In a remarkable twist, AstraZeneca (AZ) has achieved a staggering 21% 

The clinical trial will be a double-blind, randomized, placebo-controlled, first-in-human (FIH) Phase I/IIa trial in patients with generalized myasthenia gravis receiving single or multiple doses of increasing amounts of TOL2 to assess safety, tolerability, and preliminary efficacy of the investigational drug. The application is approved with the condition that Toleranzia, prior to starting the clinical trial, provides the data for bioburden, sterility and endotoxin level in the clinical trial m

On February 4, Pfizer disclosed a $2 billion impairment on its intangible assets, specifically related to Vadistuzumab (an anti-HER2 ADC) acquired from Rongchang Biopharma. This decision has ignited speculation about Pfizer potentially "returning" the drug, given that the impairment matches the initial upfront payment made to Seagen for the asset in 2021. Vadistuzumab is notable as the first ADC to receive breakthrough therapy designation from both the FDA and NMPA. It was launched in China in 2

On February 6, AstraZeneca announced it has received a notification from Chinese authorities regarding $900,000 in unpaid import taxes related to two of its cancer medications. If the company is found guilty of tax evasion, it could face fines of up to $4.5 million. The investigation has been ongoing since the arrest of the company’s former China president, Wang Lei, in late October 2024, with AstraZeneca assessing the potential impact on key market executives. In its fourth-quarter earnings rep

QUEBEC CITY--( BUSINESS WIRE )--Devonian Health Group Inc. (“ Devonian ” or the “ Corporation ”) ( TSXV: GSD; OTCQB: DVHGF ), a clinical stage corporation focused on developing unique solutions to inflammatory diseases, today announced that its pharmaceutical distribution division, Altius Healthcare Group L.P. (" Altius "), has been informed that one of its licensor does not intend to exercise its contractual license renewal option for the distribution of Dexlansoprazole for an additional term.

SAN DIEGO, Feb. 7, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora's registration statement issued in connection with Neumora's initial public offering (the "IPO") held on September 15, 2023, have until April 7, 2025 to seek appointment as lead plaintiff of the Neumora class action lawsuit. Captioned Chang v. Neumora Therapeutics, Inc., No.

Mayo Clinic recently announced separate collaborations with Microsoft Research and Cerebras Systems related to generative artificial intelligence. The goal of the partnerships is to use generative AI to personalize patient care better, significantly accelerate diagnostic time and improve accuracy, Mayo Clinic said in its Jan. 14 news release. The Rochester, Minnesota–based health provider — consistently ranked among the top in the world — has been engaged in a major push to advance what arti